PL2832366T3 - Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego - Google Patents
Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowegoInfo
- Publication number
- PL2832366T3 PL2832366T3 PL13769665T PL13769665T PL2832366T3 PL 2832366 T3 PL2832366 T3 PL 2832366T3 PL 13769665 T PL13769665 T PL 13769665T PL 13769665 T PL13769665 T PL 13769665T PL 2832366 T3 PL2832366 T3 PL 2832366T3
- Authority
- PL
- Poland
- Prior art keywords
- prevention
- treatment
- pharmaceutical composition
- gallbladder cancer
- gallbladder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012080780 | 2012-03-30 | ||
PCT/JP2013/059569 WO2013147176A1 (ja) | 2012-03-30 | 2013-03-29 | 胆嚢癌の治療及び/又は予防用医薬組成物 |
EP13769665.4A EP2832366B1 (en) | 2012-03-30 | 2013-03-29 | Pharmaceutical composition for treatment and/or prevention of gallbladder cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2832366T3 true PL2832366T3 (pl) | 2018-04-30 |
Family
ID=49260417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL13769665T PL2832366T3 (pl) | 2012-03-30 | 2013-03-29 | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
Country Status (16)
Country | Link |
---|---|
US (1) | US9428581B2 (pl) |
EP (1) | EP2832366B1 (pl) |
JP (1) | JP6107655B2 (pl) |
KR (1) | KR102052400B1 (pl) |
CN (1) | CN104203281B (pl) |
AU (1) | AU2013241043B2 (pl) |
BR (1) | BR112014024209A2 (pl) |
CA (1) | CA2869123C (pl) |
DK (1) | DK2832366T3 (pl) |
ES (1) | ES2656501T3 (pl) |
HU (1) | HUE036425T2 (pl) |
MX (1) | MX357965B (pl) |
PL (1) | PL2832366T3 (pl) |
PT (1) | PT2832366T (pl) |
RU (1) | RU2649802C2 (pl) |
WO (1) | WO2013147176A1 (pl) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2733223C (en) | 2008-08-05 | 2018-02-27 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers |
MX2011001445A (es) | 2008-08-05 | 2011-04-05 | Toray Industries | Metodo para detectar cancer. |
RU2624029C2 (ru) | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
MX340015B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
PT2532365T (pt) | 2010-02-04 | 2016-07-28 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
PT2740796T (pt) | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
BR112014002614B1 (pt) | 2011-08-04 | 2022-09-20 | Toray Industries, Inc | Anticorpo ou um fragmento do mesmo, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
EP2740793B1 (en) | 2011-08-04 | 2017-11-29 | Toray Industries, Inc. | Drug composition for cancer treatment and/or prevention |
ES2672695T3 (es) * | 2011-08-04 | 2018-06-15 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
KR101980554B1 (ko) | 2011-08-04 | 2019-05-21 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
EP2740489B1 (en) | 2011-08-04 | 2016-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
WO2013018885A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の検出方法 |
MX363136B (es) * | 2012-02-21 | 2019-03-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
WO2013125636A1 (ja) * | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
IN2014KN01715A (pl) | 2012-02-21 | 2015-10-23 | Toray Industries | |
MX360211B (es) * | 2012-02-21 | 2018-10-24 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
CA2869120C (en) | 2012-03-30 | 2023-05-23 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
RU2646466C2 (ru) | 2012-07-19 | 2018-03-05 | Торэй Индастриз, Инк. | Метод детекции рака |
JP6244912B2 (ja) | 2012-07-19 | 2017-12-13 | 東レ株式会社 | 癌の検出方法 |
KR102134088B1 (ko) | 2012-08-24 | 2020-07-14 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 |
CA2918989C (en) | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
KR102355950B1 (ko) | 2016-03-04 | 2022-01-26 | 제이엔 바이오사이언시즈 엘엘씨 | Tigit에 대한 항체 |
EP3474854A4 (en) | 2016-06-27 | 2020-02-19 | The Regents of The University of California | DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER |
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
CN106110312A (zh) * | 2016-07-14 | 2016-11-16 | 广东天普生化医药股份有限公司 | 乌司他丁在制备治疗胆囊癌药物中的用途 |
AU2017348734A1 (en) | 2016-10-28 | 2019-05-16 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
TW201837175A (zh) * | 2017-03-13 | 2018-10-16 | 美商凱特製藥公司 | 用於黑色素瘤之嵌合抗原受體及其用途 |
BR112020019935A2 (pt) * | 2018-03-30 | 2021-01-26 | Toray Industries, Inc. | medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia de um fármaco e método de tratamento e/ou prevenção do câncer |
AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
US20230165957A1 (en) | 2020-03-12 | 2023-06-01 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
JPWO2021182572A1 (pl) | 2020-03-12 | 2021-09-16 | ||
JPWO2021182570A1 (pl) | 2020-03-12 | 2021-09-16 | ||
EP4119160A4 (en) | 2020-03-12 | 2024-04-03 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
WO2021182573A1 (ja) | 2020-03-12 | 2021-09-16 | 東レ株式会社 | 癌の治療及び/又は予防のための医薬品 |
IL298111A (en) | 2020-06-02 | 2023-01-01 | Arcus Biosciences Inc | Antibodies to tigit |
AU2022298240A1 (en) | 2021-06-23 | 2024-01-18 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
JPWO2022270523A1 (pl) | 2021-06-23 | 2022-12-29 | ||
JPWO2023008461A1 (pl) | 2021-07-27 | 2023-02-02 | ||
KR20240042416A (ko) | 2021-07-27 | 2024-04-02 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
KR20240041917A (ko) | 2021-07-27 | 2024-04-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방을 위한 의약품 |
AU2022338463A1 (en) | 2021-09-03 | 2024-03-21 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
US5698396A (en) | 1995-06-07 | 1997-12-16 | Ludwig Institute For Cancer Research | Method for identifying auto-immunoreactive substances from a subject |
WO2001032910A2 (en) | 1999-10-29 | 2001-05-10 | Human Genome Sciences, Inc. | 27 human secreted proteins |
FR2761994B1 (fr) | 1997-04-11 | 1999-06-18 | Centre Nat Rech Scient | Preparation de recepteurs membranaires a partir de baculovirus extracellulaires |
AU752730B2 (en) | 1998-04-03 | 2002-09-26 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody |
US20030118599A1 (en) | 1999-04-02 | 2003-06-26 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
TW200532020A (en) | 1998-07-14 | 2005-10-01 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
RU2234942C2 (ru) | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
US6969518B2 (en) | 1998-12-28 | 2005-11-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
US6335170B1 (en) | 1999-02-22 | 2002-01-01 | Torben F. Orntoft | Gene expression in bladder tumors |
US6444425B1 (en) | 1999-04-02 | 2002-09-03 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
AU4185100A (en) | 1999-04-02 | 2000-10-23 | Corixa Corporation | Compounds for therapy and diagnosis of lung cancer and methods for their use |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
CA2404233A1 (en) | 2000-03-29 | 2001-10-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US20040029114A1 (en) | 2001-01-24 | 2004-02-12 | Eos Technology, Inc. | Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer |
RU2306952C2 (ru) | 2001-01-31 | 2007-09-27 | Байоджен Айдек Инк. | Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами |
AU2002311787A1 (en) | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
WO2002083070A2 (en) | 2001-04-10 | 2002-10-24 | Corixa Corporation | Compounds for immunotherapy and diagnosis of colon cancer and methods for their use |
WO2002092001A2 (en) | 2001-05-11 | 2002-11-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
KR100583331B1 (ko) | 2001-05-11 | 2006-05-26 | 기린 비루 가부시키가이샤 | 인간 항체 λ 경쇄 유전자를 포함하는 인간 인공 염색체 및 자손 전달 가능한 상기 인간 인공 염색체를 포함하는 비인간 동물 |
US20030190640A1 (en) | 2001-05-31 | 2003-10-09 | Mary Faris | Genes expressed in prostate cancer |
US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
JP2005535290A (ja) | 2002-02-22 | 2005-11-24 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
US20050003390A1 (en) | 2002-05-17 | 2005-01-06 | Axenovich Sergey A. | Targets for controlling cellular growth and for diagnostic methods |
US20040126379A1 (en) | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
WO2004047728A2 (en) | 2002-11-26 | 2004-06-10 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2004076682A2 (en) | 2003-02-26 | 2004-09-10 | Surromed, Inc. | Targets for controlling cellular growth and for diagnostic methods |
AU2004235382A1 (en) | 2003-04-29 | 2004-11-11 | Wyeth | Methods for diagnosing AML and MDS differential gene expression |
US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US20070048738A1 (en) | 2003-07-14 | 2007-03-01 | Mayo Foundation For Medical Education And Research | Methods and compositions for diagnosis, staging and prognosis of prostate cancer |
US20050032113A1 (en) | 2003-07-17 | 2005-02-10 | Mitsubishi Pharma Corporation | Membrane protein library for proteome analysis and method for preparing same |
EP1711525A2 (en) | 2004-01-26 | 2006-10-18 | Debiovision Inc. | Neoplasm-specific polypeptides and their uses |
MXPA06010715A (es) | 2004-03-19 | 2007-05-23 | Imclone Systems Inc | Anticuerpo del receptor del factor de crecimiento humano anti-epidermico. |
PE20060287A1 (es) | 2004-03-30 | 2006-05-16 | Glaxo Group Ltd | INMUNOGLOBULINAS DE UNION SELECTIVA A hOSM |
WO2005100998A2 (en) | 2004-04-16 | 2005-10-27 | Europroteome Ag | Membrane markers for use in cancer diagnosis and therapy |
WO2006002378A2 (en) | 2004-06-23 | 2006-01-05 | Avalon Pharmaceuticals | Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods |
CN101141981A (zh) | 2005-01-21 | 2008-03-12 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
US7858324B2 (en) | 2005-02-18 | 2010-12-28 | Children's Medical Center Corporation | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin |
NZ560976A (en) | 2005-03-11 | 2011-06-30 | Univ Johns Hopkins | Biomarkers for ovarian cancer and endometrial cancer: hepcidin |
JP2006316040A (ja) | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
US7670840B2 (en) | 2006-01-05 | 2010-03-02 | The Ohio State University Research Foundation | Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors |
EP1991701A4 (en) | 2006-02-14 | 2010-03-17 | Dana Farber Cancer Inst Inc | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING, AND TREATING CANCER |
US20100015724A1 (en) | 2006-08-17 | 2010-01-21 | Peter Hornbeck | Lysine acetylation sites |
US20080107668A1 (en) | 2006-08-30 | 2008-05-08 | Immunotope, Inc. | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
US7615349B2 (en) | 2006-09-07 | 2009-11-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Melanoma gene signature |
WO2008059252A2 (en) | 2006-11-15 | 2008-05-22 | Oxford Biomedica (Uk) Limited | Methods and composition fro t cell receptors which recognize 5t4 antigen |
ES2605646T3 (es) | 2007-10-25 | 2017-03-15 | Toray Industries, Inc. | Método para la detección de un cáncer |
JP5663834B2 (ja) | 2008-03-14 | 2015-02-04 | 東ソー株式会社 | 遺伝子組換え抗体の製造方法 |
EP2644204B1 (en) | 2008-03-18 | 2017-04-19 | Genentech, Inc. | Combinations of an Anti-HER2 antibody-drug conjugate and pertuzumab |
MX2011001445A (es) * | 2008-08-05 | 2011-04-05 | Toray Industries | Metodo para detectar cancer. |
PL2324842T3 (pl) * | 2008-08-05 | 2015-08-31 | Toray Industries | Środek indukujący odporność |
CA2733223C (en) | 2008-08-05 | 2018-02-27 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers |
JP5734978B2 (ja) | 2009-08-19 | 2015-06-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | Ffpe材料におけるインテグリン複合体検出のための抗体 |
CA2773240C (en) | 2009-09-22 | 2015-11-10 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
PT2532365T (pt) * | 2010-02-04 | 2016-07-28 | Toray Industries | Composição farmacêutica para o tratamento e/ou a prevenção do cancro |
HUE030742T2 (en) | 2010-02-04 | 2017-06-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
US8709418B2 (en) | 2010-02-04 | 2014-04-29 | Toray Industries, Inc. | Pharmaceutical composition for treating CAPRIN-1 expressing cancer |
KR101871704B1 (ko) | 2010-02-04 | 2018-06-27 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
MX340015B (es) | 2010-02-04 | 2016-06-22 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
RU2624029C2 (ru) | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
WO2012005550A2 (ko) | 2010-07-08 | 2012-01-12 | 강원대학교산학협력단 | 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법 |
ES2871092T3 (es) | 2010-07-26 | 2021-10-28 | Progastrine Et Cancers S A R L | Métodos y composiciones para la terapia del cáncer de hígado |
JP5140714B2 (ja) | 2010-10-07 | 2013-02-13 | 有限会社ナカイ | 固形食材の蜜漬け加熱装置 |
PT2740796T (pt) | 2011-08-04 | 2017-07-26 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
WO2013018885A1 (ja) * | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の検出方法 |
EP2740489B1 (en) | 2011-08-04 | 2016-10-05 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of pancreatic cancer |
KR101980554B1 (ko) | 2011-08-04 | 2019-05-21 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
BR112014002614B1 (pt) | 2011-08-04 | 2022-09-20 | Toray Industries, Inc | Anticorpo ou um fragmento do mesmo, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica |
ES2672695T3 (es) | 2011-08-04 | 2018-06-15 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer |
EP2740793B1 (en) | 2011-08-04 | 2017-11-29 | Toray Industries, Inc. | Drug composition for cancer treatment and/or prevention |
MX363136B (es) | 2012-02-21 | 2019-03-12 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
IN2014KN01715A (pl) | 2012-02-21 | 2015-10-23 | Toray Industries | |
WO2013125636A1 (ja) | 2012-02-21 | 2013-08-29 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
MX360211B (es) | 2012-02-21 | 2018-10-24 | Toray Industries | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. |
PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
CA2869120C (en) | 2012-03-30 | 2023-05-23 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of liver cancer |
WO2013188885A1 (en) * | 2012-06-15 | 2013-12-19 | Oregon Health & Science University | Non-invasive 3d imaging and measuring of anterior chamber angle of the eye |
-
2013
- 2013-03-29 PL PL13769665T patent/PL2832366T3/pl unknown
- 2013-03-29 RU RU2014143784A patent/RU2649802C2/ru active
- 2013-03-29 BR BR112014024209A patent/BR112014024209A2/pt not_active Application Discontinuation
- 2013-03-29 US US14/389,078 patent/US9428581B2/en active Active
- 2013-03-29 DK DK13769665.4T patent/DK2832366T3/en active
- 2013-03-29 HU HUE13769665A patent/HUE036425T2/hu unknown
- 2013-03-29 MX MX2014011274A patent/MX357965B/es active IP Right Grant
- 2013-03-29 CN CN201380017568.8A patent/CN104203281B/zh active Active
- 2013-03-29 EP EP13769665.4A patent/EP2832366B1/en active Active
- 2013-03-29 ES ES13769665.4T patent/ES2656501T3/es active Active
- 2013-03-29 CA CA2869123A patent/CA2869123C/en active Active
- 2013-03-29 AU AU2013241043A patent/AU2013241043B2/en active Active
- 2013-03-29 PT PT137696654T patent/PT2832366T/pt unknown
- 2013-03-29 JP JP2013522419A patent/JP6107655B2/ja active Active
- 2013-03-29 KR KR1020147026642A patent/KR102052400B1/ko active IP Right Grant
- 2013-03-29 WO PCT/JP2013/059569 patent/WO2013147176A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
BR112014024209A2 (pt) | 2018-04-10 |
WO2013147176A1 (ja) | 2013-10-03 |
PT2832366T (pt) | 2018-01-25 |
AU2013241043A1 (en) | 2014-10-09 |
EP2832366B1 (en) | 2017-11-08 |
DK2832366T3 (en) | 2018-01-22 |
ES2656501T3 (es) | 2018-02-27 |
CA2869123C (en) | 2021-03-16 |
US20150299314A1 (en) | 2015-10-22 |
JPWO2013147176A1 (ja) | 2015-12-14 |
US9428581B2 (en) | 2016-08-30 |
JP6107655B2 (ja) | 2017-04-05 |
RU2649802C2 (ru) | 2018-04-04 |
MX357965B (es) | 2018-08-01 |
KR20150002618A (ko) | 2015-01-07 |
KR102052400B1 (ko) | 2019-12-06 |
EP2832366A1 (en) | 2015-02-04 |
CN104203281B (zh) | 2019-07-26 |
HUE036425T2 (hu) | 2018-07-30 |
AU2013241043B2 (en) | 2017-11-09 |
RU2014143784A (ru) | 2016-05-27 |
MX2014011274A (es) | 2014-10-06 |
EP2832366A4 (en) | 2015-10-21 |
CA2869123A1 (en) | 2013-10-03 |
CN104203281A (zh) | 2014-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2832366T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção de cancro de vesícula biliar | |
EP2818482A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
EP2818481A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
EP2824114A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
PT2832365T (pt) | Composição farmacêutica para o tratamento e/ou prevenção do cancro hepático | |
PT2740793T (pt) | Composição de fármacos para o tratamento e/ou a prevenção de cancro | |
HUE042081T2 (hu) | Gyógyászati készítmény rák kezelésére és/vagy megelõzésére | |
PL2740795T3 (pl) | Kompozycja lekowa do leczenia nowotworu i/lub zapobiegania nowotworowi | |
PL2740798T3 (pl) | Kompozycja leku do leczenia i/lub zapobiegania nowotworom | |
PL2532365T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi | |
PL2532743T3 (pl) | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka | |
PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
PT2740489T (pt) | Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático | |
PL2740796T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu i/lub zapobiegania nowotworowi | |
PT2740794T (pt) | Composição farmacêutica para o tratamento e/ou profilaxia de cancro | |
EP2532367A4 (en) | PHARMACEUTICAL AGENT FOR THE TREATMENT AND / OR PREVENTION OF CANCER | |
EP2962693A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF CANCER | |
EP2928456A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
IL221238A0 (en) | Pharmaceutical compositions and methods for the treatment and prevention of cancer |